Literature DB >> 30993441

Hemodynamic comparison of CoreValve and SAPIEN-XT TAVI valves in Japanese patients.

Koki Shishido1, Futoshi Yamanaka2, Tomoki Ochiai2, Tsuyoshi Yamabe3, Kenichiro Noguchi3, Takashi Ota4, Yasuhiro Koide4, Hidemitsu Ogino5, Yutaka Tanaka2, Shigeru Saito2.   

Abstract

Transcatheter aortic valve implantation (TAVI) is a viable treatment option for high-risk patients with severe aortic stenosis. In Japan, TAVI can be performed using first-generation self-expandable Medtronic CoreValve or balloon-expandable Edwards SAPIEN-XT from 2012. Since the durability and hemodynamic outcomes after transcatheter heart valve (THV) implantation in Japanese patients have not been clearly elucidated, we assessed serial changes in post-TAVI THV performances over a-3-year period by transthoracic echocardiography (TTE). From January 2012 to September 2014, among 83 patients with severe aortic stenosis, 26 underwent TAVI with CoreValve and 57 underwent TAVI with SAPIEN-XT. We assessed the serial changes in first post-implant (FPI) and 3-year post procedure THV hemodynamics by TTE. Valve performance was evaluated by serial assessment of aortic valve mean pressure gradient (PG) and aortic valve area (AVA) assessments. Three-year clinical outcomes were compared between the patients with CoreValve and those with SAPIEN-XT. Seventeen patients with CoreValve and 34 patients with SAPIEN-XT had FPI and 3-year TTEs. The AVA decreased significantly from FPI to 3-year follow-up among patients with SAPIEN-XT, but not among patients with CoreValve. The mean aortic PG decreased significantly from FPI to the 3-year follow-up point among patients with CoreValve; however, it was not significantly different from those with SAPIEN-XT. The absolute change in mean PG from FPI to the 3-year follow-up point decreased significantly among those with CoreValve compared to those with SAPIEN-XT. Clinical outcomes after TAVI were similar for both devices at 3-years after TAVI. In this study, long-term clinical outcomes for CoreValve and SAPIEN XT were similar. The 3-year THV performance of both devices was maintained after TAVI. Serial change in mean aortic PGs for CoreValve decreases significantly from FPI to the 3-year follow-up point compared to that for SAPIEN-XT.

Entities:  

Keywords:  Aortic stenosis; Durability; Transcatheter aortic valve implantation; Transcatheter heart valve performance

Mesh:

Year:  2019        PMID: 30993441     DOI: 10.1007/s00380-019-01414-0

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  18 in total

1.  Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography.

Authors:  William A Zoghbi; John B Chambers; Jean G Dumesnil; Elyse Foster; John S Gottdiener; Paul A Grayburn; Bijoy K Khandheria; Robert A Levine; Gerald Ross Marx; Fletcher A Miller; Satoshi Nakatani; Miguel A Quiñones; Harry Rakowski; L Leonardo Rodriguez; Madhav Swaminathan; Alan D Waggoner; Neil J Weissman; Miguel Zabalgoitia
Journal:  J Am Soc Echocardiogr       Date:  2009-09       Impact factor: 5.251

2.  Transcatheter versus surgical aortic-valve replacement in high-risk patients.

Authors:  Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

3.  Long-term outcomes after transcatheter aortic valve implantation: insights on prognostic factors and valve durability from the Canadian multicenter experience.

Authors:  Josep Rodés-Cabau; John G Webb; Anson Cheung; Jian Ye; Eric Dumont; Mark Osten; Christopher M Feindel; Madhu K Natarajan; James L Velianou; Giussepe Martucci; Benoît DeVarennes; Robert Chisholm; Mark Peterson; Christopher R Thompson; David Wood; Stefan Toggweiler; Ronen Gurvitch; Samuel V Lichtenstein; Daniel Doyle; Robert DeLarochellière; Kevin Teoh; Victor Chu; Kevin Bainey; Kevin Lachapelle; Asim Cheema; David Latter; Jean G Dumesnil; Philippe Pibarot; Eric Horlick
Journal:  J Am Coll Cardiol       Date:  2012-10-10       Impact factor: 24.094

4.  Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature.

Authors:  Ganesh Athappan; Eshan Patvardhan; E Murat Tuzcu; Lars Georg Svensson; Pedro A Lemos; Chiara Fraccaro; Giuseppe Tarantini; Jan-Malte Sinning; Georg Nickenig; Davide Capodanno; Corrado Tamburino; Azeem Latib; Antonio Colombo; Samir R Kapadia
Journal:  J Am Coll Cardiol       Date:  2013-04-16       Impact factor: 24.094

5.  Clinical efficacy of transcatheter aortic valve replacement for severe aortic stenosis in high-risk patients: the PREVAIL JAPAN trial.

Authors:  Yoshiki Sawa; Morimasa Takayama; Kazuaki Mitsudo; Shinsuke Nanto; Shuichiro Takanashi; Tatsuhiko Komiya; Toru Kuratani; Tetsuya Tobaru; Tsuyoshi Goto
Journal:  Surg Today       Date:  2014-03-05       Impact factor: 2.549

6.  5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial.

Authors:  Michael J Mack; Martin B Leon; Craig R Smith; D Craig Miller; Jeffrey W Moses; E Murat Tuzcu; John G Webb; Pamela S Douglas; William N Anderson; Eugene H Blackstone; Susheel K Kodali; Raj R Makkar; Gregory P Fontana; Samir Kapadia; Joseph Bavaria; Rebecca T Hahn; Vinod H Thourani; Vasilis Babaliaros; Augusto Pichard; Howard C Herrmann; David L Brown; Mathew Williams; Jodi Akin; Michael J Davidson; Lars G Svensson
Journal:  Lancet       Date:  2015-03-15       Impact factor: 79.321

7.  Transcatheter aortic-valve replacement with a self-expanding prosthesis.

Authors:  David H Adams; Jeffrey J Popma; Michael J Reardon; Steven J Yakubov; Joseph S Coselli; G Michael Deeb; Thomas G Gleason; Maurice Buchbinder; James Hermiller; Neal S Kleiman; Stan Chetcuti; John Heiser; William Merhi; George Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; John Conte; Brijeshwar Maini; Mubashir Mumtaz; Sharla Chenoweth; Jae K Oh
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

8.  2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement.

Authors:  Michael J Reardon; David H Adams; Neal S Kleiman; Steven J Yakubov; Joseph S Coselli; G Michael Deeb; Thomas G Gleason; Joon Sup Lee; James B Hermiller; Stan Chetcuti; John Heiser; William Merhi; George L Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; Brijeshwar Maini; Mubashir Mumtaz; John V Conte; Jon R Resar; Vicken Aharonian; Thomas Pfeffer; Jae K Oh; Hongyan Qiao; Jeffrey J Popma
Journal:  J Am Coll Cardiol       Date:  2015-06-05       Impact factor: 24.094

Review 9.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document.

Authors:  A Pieter Kappetein; Stuart J Head; Philippe Généreux; Nicolo Piazza; Nicolas M van Mieghem; Eugene H Blackstone; Thomas G Brott; David J Cohen; Donald E Cutlip; Gerrit-Anne van Es; Rebecca T Hahn; Ajay J Kirtane; Mitchell W Krucoff; Susheel Kodali; Michael J Mack; Roxana Mehran; Josep Rodés-Cabau; Pascal Vranckx; John G Webb; Stephan Windecker; Patrick W Serruys; Martin B Leon
Journal:  J Am Coll Cardiol       Date:  2012-10-09       Impact factor: 24.094

10.  First clinical trial of a self-expandable transcatheter heart valve in Japan in patients with symptomatic severe aortic stenosis.

Authors:  Yoshiki Sawa; Shigeru Saito; Junjiro Kobayashi; Hiroshi Niinami; Toru Kuratani; Koichi Maeda; Hideaki Kanzaki; Nobuyuki Komiyama; Yutaka Tanaka; Adam Boyle; Angie Zhang; B Jane Moore; Ricardo de Medeiros
Journal:  Circ J       Date:  2014-03-21       Impact factor: 2.993

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.